Annexon, Inc. (ANNX)
3.92
-0.05
(-1.26%)
USD |
NASDAQ |
Nov 13, 16:00
3.93
+0.01
(+0.26%)
After-Hours: 19:59
Annexon Enterprise Value : 604.98M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 604.98M |
| November 12, 2026 | 614.48M |
| November 11, 2026 | 656.31M |
| November 10, 2026 | 660.11M |
| November 09, 2026 | 663.91M |
| November 06, 2026 | 658.21M |
| November 05, 2026 | 621.14M |
| November 04, 2026 | 682.92M |
| November 03, 2026 | 656.31M |
| November 02, 2026 | 608.78M |
| October 30, 2026 | 629.69M |
| October 29, 2026 | 622.09M |
| October 28, 2026 | 627.79M |
| October 27, 2026 | 574.57M |
| October 26, 2026 | 563.16M |
| October 23, 2026 | 572.66M |
| October 22, 2026 | 584.07M |
| October 21, 2026 | 593.57M |
| October 20, 2026 | 587.87M |
| October 19, 2026 | 622.09M |
| October 16, 2026 | 508.03M |
| October 15, 2026 | 544.15M |
| October 14, 2026 | 557.46M |
| October 13, 2026 | 587.87M |
| October 12, 2026 | 612.58M |
| Date | Value |
|---|---|
| October 09, 2026 | 623.99M |
| October 08, 2026 | 620.19M |
| October 07, 2026 | 622.09M |
| October 06, 2026 | 625.89M |
| October 05, 2026 | 658.21M |
| October 02, 2026 | 656.31M |
| October 01, 2026 | 643.00M |
| September 30, 2026 | 663.91M |
| September 29, 2026 | 536.52M |
| September 28, 2026 | 515.57M |
| September 25, 2026 | 450.97M |
| September 24, 2026 | 478.90M |
| September 23, 2026 | 491.13M |
| September 22, 2026 | 545.25M |
| September 21, 2026 | 552.24M |
| September 18, 2026 | 553.98M |
| September 17, 2026 | 543.51M |
| September 16, 2026 | 501.60M |
| September 15, 2026 | 499.86M |
| September 14, 2026 | 505.09M |
| September 11, 2026 | 503.35M |
| September 10, 2026 | 538.27M |
| September 09, 2026 | 578.43M |
| September 08, 2026 | 630.81M |
| September 04, 2026 | 665.73M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.335B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 160.67M |
| Savara, Inc. | 854.40M |
| Arrowhead Pharmaceuticals, Inc. | 6.959B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.22M |
| Total Expenses (Quarterly) | 51.22M |
| EPS Diluted (Quarterly) | -0.2503 |
| Earnings Yield | -26.26% |
| Normalized Earnings Yield | -26.26 |